[An experimental study on subconjunctival interleukin-1 receptor antagonist for promotion of corneal transplant survival].
To determine whether the subconjunctival application of interleukin-1 receptor antagonist (IL-1ra) can prolong the corneal graft survival in the rat model of orthotopic penetrating keratoplasty. For all experiments, F344 corneas were transplanted into LOU (major histocompatibility-disparate) eyes. Experimental groups received subconjunctival injection of 50, 100 and 200 microg IL-1ra respectively, and the control group received the same volume of 0.9% normal saline instead for consecutive 2 weeks. All transplants were evaluated for 4 weeks after surgery for signs of rejection. The mean survival time (MST) of the grafts of the experimental groups was increased significantly (t = 0.00, P < 0.01) in comparison with the control group. The MST of the IL-1ra 200 microg group was increased significantly than that of the IL-1ra 50 microg group (t = 0.00, P < 0.01). Furthermore, the IL-1ra-treated grafts had significantly less corneal inflammation, infiltration, lower levels of opacity, edema, neovascularization and rejection index compared with the control group. Subconjunctival treatment of IL-1ra has a significantly positive effect on promoting corneal allograft survival. And its effect is dosage-dependent.